The synergistic efficacy of adalimumab and pamidronate in a patient with ankylosing spondylitis.
A patient with ankylosing spondylitis, after demonstrating incomplete clinical response to adalimumab, received three monthly infusions of pamidronate along with continuing TNF-alpha blockade. Complete disappearance of the back pain was reported after the second pamidronate infusion. The perspectives of the combination therapy with TNF-alpha inhibitor and pamidronate are discussed.
Slobodin
Gleb
G
Department of Internal Medicine A, Bnai Zion Medical Center, Ruth & Bruce Rappaport Faculty of Medicine, Technion, Haifa, 31048, PO Box 4940, Israel. gslobodin@yahoo.com
Rosner
Itzhak
I
Rimar
Doron
D
Boulman
Nina
N
Rozenbaum
Michael
M
Odeh
Majed
M
D000068879:Adalimumab; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D004164:Diphosphonates / Q000627:therapeutic use*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008875:Middle Aged; D000077268:Pamidronate; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D004164:Diphosphonates; D000068879:Adalimumab; D000077268:Pamidronate